10 Reasons To Buy Durect Right Now
moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboardSee who DURECT is hiring next, click here to view […]
DRRX
KBR, Inc. Earnings Call scheduled for 8:30 am ET today
moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboardSee who DURECT is hiring next, click here to view […]
DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboardSee who DURECT is hiring next, click here to view […]
4:43 pm Durect receives Complete Response letter from FDA for POSIDUR (SABER-Bupivacaine) (stock halted)
moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboardSee who DURECT is hiring next, click here to view […]
DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine)
[PR Newswire] – CUPERTINO, Calif., Feb. 12, 2014 /PRNewswire/ — DURECT Corporation (DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for POSIDURâ„¢ (SABER®-Bupivacaine), an investigational dru moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboardSee who DURECT is hiring next, click here to […]
Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial
[at noodls] – Plans to Seek Partner and Accelerate Development of Once-Monthly Subcutaneous Formulation of Risperidone for Schizophrenia SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) — Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical … moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboardSee who DURECT is hiring next, click here to view […]
Pain Therapeutics Reports Q3 2012 Financial Results
[at noodls] – On Track With Financial Guidance for 2012 AUSTIN, Texas, Nov. 8, 2012 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the quarter and nine months ended September … moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: Pfizer Spooks Durect Investors, Creates Opportunity
[ACN Newswire] – By Jason Napodano, CFAOn November 1, 2012, Pfizer (NYSE:PFE) held a conference call ( webcast link ) to discuss its third quarter earnings and financial outlook with investors. In the past, Pfizer’s conference … moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: PTIE Down on Disappointing Pfizer Commentary and Pushback; Stock Could Trade Lower
[ACN Newswire] – By David MoskowitzShares of Pain Therapeutics (NASDAQ:PTIE) are off 25% as partner Pfizer (NYSE:PFE) noted Thursday on its earnings call that Remoxy, PTIE’s lead product, is a challenging asset … moreView todays social media effects on DRRXView the latest stocks trending across Twitter. Click to view dashboard […]
